Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence
Healy, David; Mangin, Dee
Epidemiology and Psychiatric Sciences2024
Abstract (paraphrased)
Examines why PSSD incidence/prevalence remain unquantified — inconsistent coding scatters cases across health records under vague labels, blocking the large database studies needed for clear estimates.
Plain-language summary (paraphrased)
Explains a frustrating paradox: PSSD is officially recognized, yet nobody can say how common it is, because medical coding systems have no proper label for it — cases vanish into vague categories. Understanding this gap matters for interpreting every prevalence claim in the corpus.
Why it’s in the corpus
Methods/epidemiology context; explains evidence gaps and cautions against over-interpreting prevalence figures.
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Peer-reviewed paperPSSD Discord pick
Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management
Xie, M.; Huang, P.; Wang, S.; Ma, J.; Zeng, Y.; Sun, J. · Journal (SAGE; 2026)
Systematic review (PubMed/Web of Science/Scopus to April 2024) finding persistent symptoms in up to 74% of affected cohorts beyond 6 months; pathophysiology multifactorial — 5-HT1A desensitization, neurosteroid (allopregnanolone) depletion via 5α-reductase…
HTR1APSSD-0032026PFSPSSDCore corpus - Peer-reviewed paper
Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases
Healy, David; Le Noury, Joanna; Mangin, Dee · International Journal of Risk & Safety in Medicine · 29(3-4):125-134
Drawing on reports submitted to the RxISK.org adverse-event site, the authors assembled 300 cases of persistent sexual difficulty from 37 countries after treatment with serotonin reuptake inhibiting antidepressants, finasteride-type drugs, or isotretinoin…
CROSS-0012018PFSPSSDPRSDCore corpus - Peer-reviewed paper
One hundred and twenty cases of enduring sexual dysfunction following treatment
Hogan, C.; Le Noury, J.; Healy, D.; Mangin, D. · International Journal of Risk & Safety in Medicine · 26(2):109-116
Early case series of 120 reports of enduring sexual dysfunction following drug treatment, drawn from pharmacovigilance data, helping establish the phenomenon before formal criteria existed.
CROSS-0032014PSSDCore corpus